Vivo Bio Tech Quarterly Results for Trading Insights
In Sept 2025, Vivo Bio Tech (VIVOBIOT) reported revenue ₹13 Cr and net profit ₹1 Cr — revenue -23.5% YoY. Compare with VIVOBIOT fair value estimate to assess whether the stock is under or overvalued.
VIVOBIOT Quarterly Results — Revenue, Profit & EPS Highlights
Vivo Bio Tech latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Vivo Bio Tech share price chart.
- Revenue of ₹13 Cr in Sept 2025 (+8.3% vs Mar 2025, -23.5% vs Sept 2024)
- Net Profit of ₹1 Cr in Sept 2025 (+0.0% vs Mar 2025, -80.0% vs Sept 2024)
- EBITDA of ₹6 Cr in Sept 2025 (+20.0% vs Mar 2025)
- Operating Margin of 41.0% in Sept 2025 (+0.0pp vs Mar 2025)
- Earnings Per Share of ₹0.45 in Sept 2025 (-34.8% vs Mar 2025)
Vivo Bio Tech Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VIVOBIOT quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 13 | 12 | 13 | 14 | 17 | 8.3% | -23.5% |
| Net Profit (₹ Cr) | 1 | 1 | 1 | 1 | 5 | - | - |
| EBITDA (₹ Cr) | 6 | 5 | 6 | 6 | 10 | - | - |
| EPS (₹) | 0.45 | 0.69 | 0.74 | 0.56 | 3.51 | - | - |
| Operating Margin (%) | 41.0% | 41.0% | 44.0% | 41.0% | 47.0% | - | - |
VIVOBIOT Share Price Trend — 1-Year Movement Across Quarterly Results
Vivo Bio Tech 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore VIVOBIOT share price data to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VIVOBIOT vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Vivo Bio Tech latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1880.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 144.6 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6893.0 | 2,860 | 689 | +7.1% | - | 24.1% | 265.4 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4429.2 | 3,219 | 591 | +11.3% | - | 18.4% | 252.5 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1399.5 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 203.7 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1321.9 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 498.8 |
All amounts in ₹ Crores